TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Presence and activation of tissue-resident memory lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Volemia status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder Leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: modified visual analog scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Motor imagery capacities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Nightingale Symptom Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment adherence and engagement
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Acceptability of the treatment
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Percentage of ZFXN response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum TSH levels within the normal reference range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum Observed Serum Concentration (Cmax) of Cetrelimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time Zero to Last Measurable Concentration (AUC[0-last]) of Cetrelimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Elimination Half-life (t1/2) of Cetrelimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Systemic Clearance of Cetrelimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neck and Low Back Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: VAS (Visuoanalogic scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AFAS (American Foot and Ankle Score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 1-year overall survival probability
Endpoint domain: Mortality/survival
Primary endpoint: Sentiments about back vulnerability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of participants meeting primary safety composite endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Number of viruses with antibody neutralization response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patients free of disease progression
Endpoint domain: Mortality/survival
Primary endpoint: Preparedness to care for a person with heart failure
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: MRI scar score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of virtual reality pathway
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number and percentage of latent tuberculosis diagnosis
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of possible Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary function analysis by UCLA-EPIC scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary function analysis by IPSS-QoL scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Erectile function analysis by IIEF-15 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change in blood vessel dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frontal alpha asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood Pressure Prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Whistleblowing intention of nurses
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: formation of oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of episodes of AF lasting 5 min or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of CHIP in acute HF patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in blood velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference in mmHg between Right atrial pressure (RAP) and Central venous pressure (CVP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: KREC and CD19 of B-cells in offspring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody production post vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency and severity of infections
Endpoint domain: Adverse events/effects
Primary endpoint: SpO2 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-tumor activity of AVB-S6-500 in combination with cabozantinib (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Anti-tumor activity of AVB-S6-500 alone (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number and Proportion of patients flagged by the tool
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients with failure or success
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of glucocorticoid (GC) deficiency / adrenal insufficiency and adrenal crisis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of hospitalizations related to congenital adrenal hyperplasia (CAH)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change from baseline in morning (before 11:00 AM) serum androstenedione (A4) over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: effectiveness of dexamethasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary fluid content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of statins changed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate at which LDL cholesterol remains below 55 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Spasticity Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl Meyer Assessment Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurophysiological Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ultrasonographic Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Stress Scale-10 (PSS-10)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reference values for oesophageal scintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of Urine Protein to Creatine Ratio (UPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Diagnostic accuracy of stool Ag test for H. pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiographic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epworth sleepiness scale (ESS)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Speech intelligibility in Noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum perineal wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: metabolism of each amino acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adjusted area under the serial spirometry FEV1-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Arterial access related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Risk factors for relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognostic tool for relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in serum levels of Interleukin-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decreases in depressive severity (IDS-CR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decreases in depressive severity (SDQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Operative bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of stimuli identified as target items
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in 3D aortic displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in pulse wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in oscillatory shear index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of dISF biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DLCO%pred (carbon monoxide diffusing capacity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Subjects Reporting Unsolicited Adverse Events Within 1 Month After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Score of Craving Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Score of Withdrawal Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total oocytes obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Metaphase II (MII) oocytes obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Digestive and extradigestive symptoms of NCGS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants Persisting on Treatment With Vedolizumab IV Compared to Participants With Treatment Change up to 24 Months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Discontinued Vedolizumab Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Metacognition Scale-30
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Self-Efficacy-Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment Motivation Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Family Hardiness Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Retinal Examination (RE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroretinography (ECC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck Disability Index scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: width of the alveolar ridge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cobb Angle prediction accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Pain Severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: P kortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mental health level of the youths
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Somatization symptoms, anxiety, and depression status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived level of social support system
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of allogeneic blood products transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Major Depression Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diagnostic performance of CBCT model for osteoporosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Error Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Improved tear film osmolarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Three dimensional motion analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drop jump landing test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Environmental Attitude Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Magnetic Resonance Imaging at 6 months post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnetic Resonance Imaging at 12 months post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnetic Resonance Imaging at 24 months post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FDG influx into WAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IrAE time-to-detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of study subjects who achieved a response to treatment (injections)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of study subjects who achieved a response to treatment (tablets)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Illness Perception Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cough stress test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paediatric quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Parenting stress Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of rebound pain
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in pain perception assessed using a 100 mm Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pain perception assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ®)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in life quality assessed using the SF36 Health Survey (SF-36v2®)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in sleep quality assessed using the Pittsburgh Sleep Quality Index (PSQI®)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Engagement in addiction treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient hospitalization-level area under curve (AUC) for identification of sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Dose Excreted in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Dose Excreted in Feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Total Recovery (Urine + Feces)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute Oral BA for RO7049389
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood levels of Zn2+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fecal Zn2+ concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: accelerometer-based assessment of physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preliminary effect size estimate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean nausea score per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ALS Functional Rating Scale-Revised (ALSFRS-R) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to infinity (AUC) of alprazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC(0-t)) of alprazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of alprazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction of hyperbilirubinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of HY01
Endpoint domain: Adverse events/effects
Primary endpoint: Immunologic intratumoral changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in antibiotic prescribing rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of mature (MII) oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: change from baseline HBV-DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: change from baseline level of blood lipid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of biomarkers for early detection of diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease of spleen size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptoms burden
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: VV-ECMO auxiliary time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vergence ranges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anorectal manometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline of Visual Analog Scale for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of Roland Morris Disability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in baseline of EuroQol (EQ5D-5L) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Neck Pain Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Blood and CSF levels of circulating free DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction to active labor time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active labor to delivery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regional FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: regional FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in pain pressure threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Escalation of respiratory therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Average daily ischemic risk (ADIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average daily bleeding risk (ADBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Chairside time taken
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of eligible patients that give consent and are randomized
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of randomized patients that receive allocated intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of randomized patients receiving masked allocated intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of randomized patients assessed for NEC-related outcomes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use